
    
      This is a phase Ia study, first-in-human, open-label, dose-escalation study of BPI-9016M
      administered orally once daily (QD) to patients with locally advanced or metastatic solid
      tumors.The study is designed to evaluate the safety, tolerability, and pharmacokinetics of
      single dose and multiple doses of BPI-9016M.

      All patients will be followed up for adverse events during the study treatment and 28 days
      after the last dose of study drug. Subjects of this study will be permitted to continue
      therapy only when BPI-9016M is well tolerated, and tumor response or stable disease is seen.
    
  